RTP Mobile Logo

Monday, June 4, 2018, Chicago, IL, 7:00 PM – 9:30 PM

Consensus or Controversy? Clinical Investigators Provide Perspectives on Practical Issues and Ongoing Research Related to the Management of Breast Cancer

Event Details

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

6:30 PM – 7:00 PM (Central Time) — Registration and Dinner Buffet
7:00 PM – 9:30 PM (Central Time) — Educational Meeting

Meeting Room:
Grand Ballroom (Level 2)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
Harold J Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Angelo Di Leo, MD, PhD
Head of the Sandro Pitigliani Department of Medical Oncology
Hospital of Prato
Istituto Toscano Tumori
Prato, Italy

Sara A Hurvitz, MD
Associate Professor of Medicine
Director, Breast Oncology Program, Division of Hematology/Oncology
University of California, Los Angeles
Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit
Los Angeles, California
Co-Director, Santa Monica-UCLA Outpatient Oncology Practices
Santa Monica, California

Mark Robson, MD
Clinic Director, Clinical Genetics Service
Associate Attending Physician, Clinical Genetics and Breast Cancer Medicine
Associate Member, Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine, Weill Medical College of Cornell University
New York, New York

Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

George W Sledge Jr, MD
Professor of Medicine
Chief, Division of Oncology
Department of Medicine
Stanford University School of Medicine
Stanford, California

Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or the Conquer Cancer Foundation.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc, Lilly and Merck.


Meeting Format and Agenda

Prior to this event, each faculty member will be asked to complete a case-based Consensus or Controversy (CoC) survey designed to document his or her usual approach to a variety of clinical scenarios and management questions provided by a group of 5 community-based medical oncologists. During the program, the responses of the faculty to specific CoC questions will be graphically displayed for the audience. Short didactic presentations will also be included to provide a formal review of available data and ongoing trials.

MODULE 1: Optimal Treatment Strategies for Patients with Localized HER2-Positive Breast Cancer (BC) — Dr Hurvitz

  • Results from the Phase III APHINITY trial evaluating the addition of pertuzumab to chemotherapy and trastuzumab as adjuvant therapy for patients with HER2-positive early BC; clinical implications of recent FDA approval
  • Optimal approach to adjuvant therapy in individuals who have received trastuzumab and pertuzumab in the neoadjuvant setting
  • FDA approval of neratinib as extended adjuvant therapy; patient selection and clinical factors guiding its use in practice
  • Prevention, recognition and management of toxicities associated with pertuzumab and neratinib

MODULE 2: Current Role of Genomic Assays in the Management of ER-Positive Early BC — Dr Burstein

  • Results of the Phase III TAILORx trial of chemotherapy and endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate 21-gene Recurrence Score®
  • Other recent data sets informing the use of molecular profiling to personalize adjuvant therapy for patients with ER-positive early BC
  • Current clinical role of genomic assays in decision-making for patients with node-negative and node-positive, ER-positive early BC
  • Available data with and practical use of genomic assays to guide the use of neoadjuvant or extended adjuvant therapy

MODULE 3: Therapeutic Considerations for Patients with ER-Positive, HER2-Negative Metastatic BC (mBC) — Dr Di Leo

  • Available data with and FDA-approved indications for abemaciclib, palbociclib and ribociclib
  • Comparative activity, side effects and CNS penetration of available CDK4/6 inhibitors
  • Current clinical role of CDK4/6 inhibitors in premenopausal patients
  • Ongoing trials evaluating other novel treatment strategies for patients with ER-positive, HER2-negative metastatic disease (eg, (neo)adjuvant CDK4/6 inhibitors, PI3 kinase inhibitors)

MODULE 4: Protocol and Nonresearch Decision-Making for Patients with HER2-Positive mBC — Dr Sledge

  • Treatment options for patients experiencing disease progression after receiving (neo)adjuvant pertuzumab/trastuzumab/chemotherapy
  • Published research data examining the use of combined endocrine and anti-HER2 blockade for patients with triple-positive mBC
  • Optimal therapeutic approach for patients with HER2-positive CNS metastases
  • Activity of CDK4/6 inhibitors in patients with HER2-positive disease
  • Novel agents and strategies under development for HER2-positive mBC (eg, tucatinib, margetuximab)

MODULE 5: Role of PARP Inhibition in the Management of BC — Dr Robson

  • Design, eligibility requirements and major efficacy and safety findings from the Phase III OlympiAD trial comparing olaparib to chemotherapy in patients with metastatic HER2-negative BC harboring a germline BRCA1/2 mutation
  • Implications of recent FDA approval of olaparib on current BRCA testing guidelines and role, if any, of olaparib in patients with germline and somatic alterations beyond BRCA1/2
  • Available clinical trial data with and ongoing evaluation of other PARP inhibitors under evaluation in BC
  • Biologic rationale for and ongoing clinical trials assessing the efficacy and safety of PARP inhibitors in combination with other systemic approaches (eg, chemotherapy, immunotherapy)

MODULE 6: Immune Checkpoint Inhibitors and Other Emerging Therapeutic Strategies — Dr Rugo

  • Activity and duration of response with anti-PD-1/PD-L1 antibodies in patients with mBC
  • Ongoing studies evaluating anti-PD-1/PD-L1 antibodies alone or in combination with other systemic approaches in patients with mBC
  • Available clinical trial data documenting the presence of genomic alterations in BC and potential benefit of targeted therapies
  • Other promising therapies under investigation

CE Information

Target Audience:
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.

Learning Objectives and Goals:
At the conclusion of this activity, participants should be able to:

  • Consider published data to guide the use of biomarkers and genomic classifiers to assess risk and customize therapy for patients with hormone receptor-positive breast cancer in the neoadjuvant, adjuvant and extended adjuvant settings.
  • Appraise available and emerging research evidence to individualize the selection and duration of neoadjuvant, adjuvant and/or extended adjuvant therapy for patients with HER2-overexpressing early breast cancer.
  • Implement a long-term clinical plan for the management of metastatic HER2-positive breast cancer, incorporating existing and investigational targeted treatments.
  • Develop an evidence-based algorithm for the treatment of advanced hormone receptor-positive pre- and postmenopausal breast cancer, including endocrine, biologic and chemotherapeutic agents.
  • Consider published research and patient preferences in the selection and sequencing of available and investigational therapeutic agents for metastatic ER/PR-negative, HER2-negative breast cancer.
  • Appreciate the recent FDA approval of olaparib for patients with HER2-negative metastatic breast cancer harboring a germline BRCA mutation, and discern how this agent can be appropriately and safely integrated into routine clinical practice.
  • Develop an understanding of the mechanisms of action, available data and potential clinical roles of investigational compounds in preparation for their potential introduction into future clinical practice.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc, Lilly and Merck.


Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center.



Thank you for your interest in our educational program.  At this time, online preregistration is closed. However, seats are still available for the conference. Onsite registration will be open starting at 6:30 PM (Central Time) on Monday, June 4th. If you are interested in attending, please visit our registration desk in the Grand Ballroom foyer located on the second level of the Hilton Chicago (720 Michigan Avenue, Chicago, IL).

Please note, onsite registrant seating will be prioritized for healthcare professionals directly involved in the treatment of patients. If you have any questions, please feel free to contact us via email at: Meetings@ResearchToPractice.com or call (800) 233-6153.